162. Pemphigoid Clinical trials / Disease details
Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05061771 (ClinicalTrials.gov) | May 6, 2022 | 15/9/2021 | Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | Bullous Pemphigoid | Drug: nomacopan (rVA576);Other: Placebo | AKARI Therapeutics | NULL | Withdrawn | 18 Years | 99 Years | All | 0 | Phase 3 | United States;Germany;Netherlands;Poland |